Literature DB >> 18821648

Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations.

D Aletaha1, R Landewe, T Karonitsch, J Bathon, M Boers, C Bombardier, S Bombardieri, H Choi, B Combe, M Dougados, P Emery, J Gomez-Reino, E Keystone, G Koch, T K Kvien, E Martin-Mola, M Matucci-Cerinic, K Michaud, J O'Dell, H Paulus, T Pincus, P Richards, L Simon, J Siegel, J S Smolen, T Sokka, V Strand, P Tugwell, D van der Heijde, P van Riel, S Vlad, R van Vollenhoven, M Ward, M Weinblatt, G Wells, B White, F Wolfe, B Zhang, A Zink, D Felson.   

Abstract

OBJECTIVE: To make recommendations on how to report disease activity in clinical trials of rheumatoid arthritis (RA) endorsed by the European League Against Rheumatism (EULAR) and the American College of Rheumatology (ACR).
METHODS: The project followed the EULAR standardized operating procedures, which use a three-step approach: 1) expert-based definition of relevant research questions (November 2006); 2) systematic literature search (November 2006 to May 2007); and 3) expert consensus on recommendations based on the literature search results (May 2007). In addition, since this is the first joint EULAR/ACR publication on recommendations, an extra step included a meeting with an ACR panel to approve the recommendations elaborated by the expert group (August 2007).
RESULTS: Eleven relevant questions were identified for the literature search. Based on the evidence from the literature, the expert panel recommended that each trial should report the following items: 1) disease activity response and disease activity states; 2) appropriate descriptive statistics of the baseline, the endpoints and change of the single variables included in the core set; 3) baseline disease activity levels (in general); 4) the percentage of patients achieving a low disease activity state and remission; 5) time to onset of the primary outcome; 6) sustainability of the primary outcome; 7) fatigue.
CONCLUSION: These recommendations endorsed by EULAR and ACR will help harmonize the presentations of results from clinical trials. Adherence to these recommendations will provide the readership of clinical trials with more details of important outcomes, while the higher level of homogeneity may facilitate the comparison of outcomes across different trials and pooling of trial results, such as in meta-analyses.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18821648     DOI: 10.1002/art.24123

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  60 in total

1.  A multidimensional model of fatigue in patients with rheumatoid arthritis.

Authors:  Perry M Nicassio; Sarah R Ormseth; Mara K Custodio; Michael R Irwin; Richard Olmstead; Michael H Weisman
Journal:  J Rheumatol       Date:  2012-06-01       Impact factor: 4.666

Review 2.  How is recovery from low back pain measured? A systematic review of the literature.

Authors:  Steven J Kamper; Tasha R Stanton; Christopher M Williams; Christopher G Maher; Julia M Hush
Journal:  Eur Spine J       Date:  2010-06-16       Impact factor: 3.134

Review 3.  Biologic agents in rheumatology: unmet issues after 200 trials and $200 billion sales.

Authors:  John P A Ioannidis; Fotini B Karassa; Eric Druyts; Kristian Thorlund; Edward J Mills
Journal:  Nat Rev Rheumatol       Date:  2013-09-03       Impact factor: 20.543

4.  The landscape of comparative effectiveness research in rheumatology.

Authors:  Esi Morgan DeWitt; Hermine I Brunner
Journal:  Nat Rev Rheumatol       Date:  2013-09-24       Impact factor: 20.543

5.  Comparison of the efficacy and tolerability of tocilizumab, sarilumab, and sirukumab in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials.

Authors:  Sang-Cheol Bae; Young Ho Lee
Journal:  Clin Rheumatol       Date:  2018-02-05       Impact factor: 2.980

6.  Responsiveness of Patient-Reported Outcomes Measurement Information System Measures in Rheumatoid Arthritis Patients Starting or Switching a Disease-Modifying Antirheumatic Drug.

Authors:  Alyssa Wohlfahrt; Clifton O Bingham; Wendy Marder; Kristine Phillips; Marcy B Bolster; Larry W Moreland; Zhi Zhang; Tuhina Neogi; Yvonne C Lee
Journal:  Arthritis Care Res (Hoboken)       Date:  2019-04       Impact factor: 4.794

7.  Comparative efficacy and safety of biosimilar adalimumab and originator adalimumab in combination with methotrexate in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials.

Authors:  Sang-Cheol Bae; Young Ho Lee
Journal:  Clin Rheumatol       Date:  2018-02-01       Impact factor: 2.980

8.  Presence of power Doppler synovitis in rheumatoid arthritis patients with synthetic and/or biological disease-modifying anti-rheumatic drug-induced clinical remission: experience from a Chinese cohort.

Authors:  Yan Geng; Jingjing Han; Xuerong Deng; Zhuoli Zhang
Journal:  Clin Rheumatol       Date:  2014-04-29       Impact factor: 2.980

Review 9.  EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs.

Authors:  Josef S Smolen; Robert Landewé; Ferdinand C Breedveld; Maxime Dougados; Paul Emery; Cecile Gaujoux-Viala; Simone Gorter; Rachel Knevel; Jackie Nam; Monika Schoels; Daniel Aletaha; Maya Buch; Laure Gossec; Tom Huizinga; Johannes W J W Bijlsma; Gerd Burmester; Bernard Combe; Maurizio Cutolo; Cem Gabay; Juan Gomez-Reino; Marios Kouloumas; Tore K Kvien; Emilio Martin-Mola; Iain McInnes; Karel Pavelka; Piet van Riel; Marieke Scholte; David L Scott; Tuulikki Sokka; Guido Valesini; Ronald van Vollenhoven; Kevin L Winthrop; John Wong; Angela Zink; Désirée van der Heijde
Journal:  Ann Rheum Dis       Date:  2010-05-05       Impact factor: 19.103

Review 10.  Outcome measures in inflammatory rheumatic diseases.

Authors:  Jaap Fransen; Piet L C M van Riel
Journal:  Arthritis Res Ther       Date:  2009-10-14       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.